Investing

Solid Biosciences : SLDB

SLDB

Stock Data

$5.87

$0.01 (0.17%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Solid Biosciences Inc. focuses on creating innovative therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia. With a leading product candidate, SGT-003, aimed at Duchenne muscular dystrophy, the company is at the forefront of gene therapy research. It also explores treatments for cardiac conditions like BAG3-mediated dilated cardiomyopathy. Based in Massachusetts, Solid Biosciences is pioneering in dual gene expression technology and has partnerships to advance gene therapy development.

All Solid Biosciences Articles

2 Articles

Trey Thoelcke | Feb 18, 2024 at 11:20 AM EST

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted…

Trey Thoelcke | Jan 20, 2024 at 10:49 AM EST

More Big Warren Buffett Purchases Highlight Recent Insider Buying

Insider buying was somewhat slow in the middle of January, but some purchases by Warren Buffett's Berkshire Hathaway made headlines.